UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Adipocytes Cause Leukemia Cell Resistance to L-Asparaginase via Release of Glutamine

Cancer research (Chicago, Ill.), 2013-05, Vol.73 (10), p.2998-3006

2013

Volltextzugriff (PDF)

Glutaminase activity determines cytotoxicity of l -asparaginases on most leukemia cell lines

Leukemia research, 2015-07, Vol.39 (7), p.757-762

2015

Volltextzugriff (PDF)

Adipocytes Impair Leukemia Treatment in Mice

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7867-7874

2009

Volltextzugriff (PDF)

Asparaginases: Biochemical Pharmacology and Modes of Drug Resistance

Anticancer research, 2012-07, Vol.32 (7), p.2423-2437

AVRAMIS, Vassilios I

2012

Volltextzugriff (PDF)

Immunogenicity of Native or Pegylated E. coli and Erwinia Asparaginases Assessed by ELISA and Surface Plasmon Resonance (SPR-Biacore) Assays of IgG Antibodies (Ab) in Sera from Patients with Acute Lymphoblastic Leukemia (ALL)

Anticancer research, 2009-01, Vol.29 (1), p.299-302

2009

Volltextzugriff (PDF)

Is glutamine depletion needed in ALL disease?

Blood, 2014-06, Vol.123 (23), p.3532-3533

Avramis, Vassilios I.

2014

Volltextzugriff (PDF)

Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

Clinical cancer research, 2004-08, Vol.10 (16), p.5335-5341

2004

Volltextzugriff (PDF)

Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases

Clinical cancer research, 2015-01, Vol.21 (2), p.230-232

Avramis, Vassilios I

2015

Volltextzugriff (PDF)

Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia

Journal of clinical oncology, 2014-03, Vol.32 (9), p.905-911

2014

Volltextzugriff (PDF)

Pharmacoanalytical Assays of Erwinia Asparaginase (Erwinase) and Pharmacokinetic Results in High-risk Acute Lymphoblastic Leukemia (HR ALL) Patients: Simulations of Erwinase Population PK-PD Models

Anticancer research, 2007-07, Vol.27 (4C), p.2561-2572

2007

Volltextzugriff (PDF)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

International journal of nanomedicine, 2006-01, Vol.1 (3), p.241-254

2006

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations : The past, the present and recommendations for the future

Clinical pharmacokinetics, 2005-01, Vol.44 (4), p.367-393

2005

Volltextzugriff (PDF)

Asparaginases: a successful class of drugs against leukemias and lymphomas

Journal of pediatric hematology/oncology, 2011-12, Vol.33 (8), p.573-579

Avramis, Vassilios I

2011

Volltextzugriff (PDF)

Deamination of Glutamine is a Prerequisite for Optimal Asparagine Deamination by Asparaginases In Vivo (CCG-1961)

Anticancer research, 2004-03, Vol.24 (2C), p.1121-1125

2004

Volltextzugriff (PDF)

Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group report

Cancer, 2015-12, Vol.121 (23), p.4205-4211

2015

Volltextzugriff (PDF)

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia

Blood, 2007-04, Vol.109 (7), p.2744-2750

2007

Volltextzugriff (PDF)

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

Pediatric blood & cancer, 2015-12, Vol.62 (12), p.2140-2149

2015

Volltextzugriff (PDF)

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961

Journal of pediatric hematology/oncology, 2004-04, Vol.26 (4), p.217-226

2004

Volltextzugriff (PDF)

Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice

Pharmacological research, 2010-05, Vol.61 (5), p.385-390

2010

Volltextzugriff (PDF)

Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients

Journal of pediatric hematology/oncology, 2007-04, Vol.29 (4), p.239-247

2007

Volltextzugriff (PDF)

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG-1941)

Pediatric Blood & Cancer, 2006-08, Vol.47 (2), p.141-146

2006

Volltextzugriff (PDF)

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

Cancer chemotherapy and pharmacology, 2003-10, Vol.52 (4), p.307-318

2003

Volltextzugriff (PDF)

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

British journal of haematology, 2001-12, Vol.115 (4), p.983-990

2001

Volltextzugriff (PDF)

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

Cancer chemotherapy and pharmacology, 2002-12, Vol.50 (6), p.479-489

2002

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(92)
Dissertationen
(2)

Sprache

Englisch
(94)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(62)
Science & Technology
(62)
Humans
(56)
Oncology
(46)
Biological And Medical Sciences
(40)
Medical Sciences
(39)
Pharmacology. Drug Treatments
(33)
Antineoplastic Agents
(30)
Child
(27)
Male
(25)
Precursor Cell Lymphoblastic Leukemia-Lymphoma - Drug Therapy
(25)
Female
(21)
Child, Preschool
(19)
Chemotherapy
(17)
Adolescent
(14)
Asparaginase - Administration & Dosage
(14)
Pharmacology & Pharmacy
(14)
Infant
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
General Aspects
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adipocytes Cause Leukemia Cell Resistance to L-Asparaginase via Release of Glutamine

Glutaminase activity determines cytotoxicity of l -asparaginases on most leukemia cell lines

Adipocytes Impair Leukemia Treatment in Mice

Asparaginases: Biochemical Pharmacology and Modes of Drug Resistance

Immunogenicity of Native or Pegylated E. coli and Erwinia Asparaginases Assessed by ELISA and Surface Plasmon Resonance (SPR-Biacore) Assays of IgG Antibodies (Ab) in Sera from Patients with Acute Lymphoblastic Leukemia (ALL)

Is glutamine depletion needed in ALL disease?

Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases

Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia

Pharmacoanalytical Assays of Erwinia Asparaginase (Erwinase) and Pharmacokinetic Results in High-risk Acute Lymphoblastic Leukemia (HR ALL) Patients: Simulations of Erwinase Population PK-PD Models

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations : The past, the present and recommendations for the future

Asparaginases: a successful class of drugs against leukemias and lymphomas

Deamination of Glutamine is a Prerequisite for Optimal Asparagine Deamination by Asparaginases In Vivo (CCG-1961)

Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group report

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's Cancer Group Study

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961

Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice

Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG-1941)

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

Suchergebnisse filtern